Platinum-based doublet chemotherapy

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., The First Hospital of Hebei Medical University, West China Hospital

Conditions

Advanced Solid TumorsCarcinoma, Non-Small-Cell Lung (NSCLC)Non Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)Ovarian Cancer

Phase 1

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Active, not recruitingNCT04626635

Regeneron PharmaceuticalsAdvanced Solid Tumors

Start: 2020-12-21End: 2027-03-05Updated: 2026-07-02

Phase 2

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Not yet recruitingNCT06211023

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ovarian Cancer

Start: 2024-02-15End: 2026-06-15Target: 520Updated: 2024-01-18

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

RecruitingNCT07855965

West China HospitalCarcinoma, Non-Small-Cell Lung (NSCLC)

Start: 2026-09-10End: 2033-08-05Target: 40Updated: 2026-10-02

Phase 4

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.Non Small Cell Lung Cancer

Start: 2021-10-25End: 2024-08-15Target: 328Updated: 2021-10-29

Unknown Phase

Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

CompletedNCT07053215

The First Hospital of Hebei Medical UniversityNon-small Cell Lung Cancer (NSCLC)

Start: 2020-12-01End: 2024-12-01Updated: 2025-07-08

Related Papers

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2025-05-28

A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.

Journal of Clinical Oncology2024-06-017 citations

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

Journal of Clinical Oncology2024-01-20

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

Journal of Clinical Oncology2023-01-245 citations

735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results

Regular and Young Investigator Award Abstracts2022-11-013 citations

535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-014 citations